Search Result

Results for "

radioactive

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (3) Adenosine Receptor (1) Apoptosis (1) Bacterial (2) Biochemical Assay Reagents (13) Bombesin Receptor (1) Cannabinoid Receptor (1) CD38 (1) CXCR (1) Cytochrome P450 (1) DNA-PK (1) DNA/RNA Synthesis (1) Drug Derivative (3) Drug Intermediate (4) Drug Isomer (2) EGFR (2) Endogenous Metabolite (1) FAP (5) Ferroptosis (1) Fluorescent Dye (2) GABA Receptor (1) Glycoprotein VI (1) HDAC (1) Histone Methyltransferase (1) iGluR (1) Integrin (2) Interleukin Related (1) Isotope-Labeled Compounds (2) Microtubule/Tubulin (1) Neurokinin Receptor (2) Nucleoside Antimetabolite/Analog (1) P2X Receptor (1) PD-1/PD-L1 (1) Phosphodiesterase (PDE) (1) Prostaglandin Receptor (1) PSMA (7) Radionuclide-Drug Conjugates (RDCs) (21) Reference Standards (1) Ser/Thr Protease (1) STING (1)
By Research Areas:	Cancer (45) Cardiovascular Disease (2) Endocrinology (2) Infection (2) Inflammation/Immunology (5) Metabolic Disease (3) Neurological Disease (9)
Click Chemistry:	DBCO (1) Alkynes (1)
Oligonucleotides:	Nucleotide Analogs (1) Adenine Nucleotide (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-43869

Vipivotide tetraxetan Ligand-Linker Conjugate PSMA-617 Ligand-Linker Conjugate	ADC Linker	Cancer
Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is a complex composed of pharmacophore group Glutamate-urea-Lysine peptide coupling linker, which can be used to synthesize Vipivotide tetraxetan (PSMA-617). Glutamate-urea-Lysine selectively binds to prostate-specific membrane antigen (PSMA) .

HY-100138

2-Aminoethyl-mono-amide-DOTA-tris(tBu ester)	Radionuclide-Drug Conjugates (RDCs) ADC Linker	Cancer
2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) is a metal chelator precursor containing a DOTA macrocyclic structure. DOTA can form highly stable complexes with metal ions (such as ⁶⁸Ga, ¹⁷⁷Lu) through four nitrogen atoms and four carboxylic acid groups to mediate targeted delivery of radionuclides. The tert-butyl ester group (tBu ester) of 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) also protects the carboxylic acid group during synthesis, and forms a free carboxyl group after deprotection reaction for coupling with targeting molecules (such as antibodies, peptides). 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) may be combined with tumor pre-targeting systems through bioorthogonal reactions (such as reverse electron demand Diels-Alder reaction) to study radioactive imaging or therapy of tumor tissues, and is mainly used in tumor pre-targeting research in the field of nuclear medicine .

HY-134797

p-SCN-Bn-deferoxamine 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
P-SCN-Bn-deferoxamine is a bifunctional chelating agent that can link radioactive metal nuclides (such as Zr-89) and biological targeting molecules (such as antibodies). P-SCN-Bn-deferoxamine can be used for the research of immune PET imaging .

HY-W782083

p-SCN-Bn-NOTA trihydrochloride	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Bombesin Receptor EGFR	Cancer
p-SCN-Bn-NOTA trihydrochloride is a macrocyclic chelator. p-SCN-Bn-NOTA trihydrochloride can be covalently coupled to molecules such as peptides through the thiocyanate group to form hexacoordinate copper (such as ⁶⁴Cu) complexes. p-SCN-Bn-NOTA trihydrochloride specifically binds to GRPR or EGFR highly expressed on the surface of tumor cells, mediating tumor enrichment of radioactive probes. p-SCN-Bn-NOTA trihydrochloride can be used to study malignant tumors expressing GRPR or EGFR, such as prostate cancer and colorectal cancer .

HY-W1124925

DOTA-GPC3 targeting peptide 2	Radionuclide-Drug Conjugates (RDCs) Glycoprotein VI	Cancer
DOTA-GPC3 targeting peptide 2 (Sequence 30) is a RDC peptide targeting GPC3, with K_d of 0.3 nM. DOTA-GPC3 targeting peptide 2 is composed of DOTA and GPC3 targeting peptide 2. DOTA-GPC3 targeting peptide 2 can be labeled with radioactive elements .

HY-158067

Deferoxamine-DBCO DFO-DBCO	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Cancer
Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as ⁸⁹Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonal antibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors .

HY-W008951

Ethylenediaminetetra(methylenephosphonic acid) EDTMP	Radionuclide-Drug Conjugates (RDCs)	Neurological Disease Cancer
Ethylenediaminetetramethylenephosphonic acid (EDTMP) is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with ¹⁵³Sm and ¹⁷⁷Lu. Ethylenediaminetetramethylenephosphonic acid is used to study palliative therapy for pain associated with multiple bone metastatic cancers .

HY-P10729A

DOTA-Bombesin (1-14) TFA	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Bombesin (1-14) TFA is composed of chelator DOTA and Bombesin (HY-P0195). DOTA-Bombesin (1-14) TFA is used for research of cancer through combination with radioactive elements. DOTA-Bombesin (1-14)TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-N10348

Progoitrin	Others Drug Derivative	Endocrinology
Progoitrin is a sulfur-containing glucosinolate, as well as a naturally occurring orally active thioglycoside. Progoitrin acts as a hepatotoxin and antithyroid agent. Progoitrin is quantitatively converted to goitrin in vivo, including via a gastrointestinal hydrolysis pathway that does not require exogenous myrosinase, thereby blocking the organification of iodine in the thyroid gland and inhibiting the uptake and accumulation of radioactive iodine. Progoitrin can be used in studies related to Graves' disease .

HY-P5290

HYNIC-PSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as ¹⁸⁸Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research . HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10273A

DOTA-Octreotide TFA	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-163080S

Selenium-77 ⁷⁷Se	Isotope-Labeled Compounds	Others
Selenium-77 ( ⁷⁷Se) is a stable (non-radioactive) isotope of Selenium. Selenium-77 is both naturally occurring and produced by fission.

HY-P10913

HYNIC-UBI29-41	Bacterial	Infection
HYNIC-UBI29-41 is composed of a bifunctional chelator HYNIC and an antimicrobial peptide UBI 29-41 (HY-P10364) (HY-P10364). HYNIC-UBI29-41 retains the antibacterial properties of UBI 29-41, and exhibits good affinity to Gram-positive and Gram-negative bacteria. HYNIC-UBI29-41 can be used as an imaging agent for bacterial infection detection in mouse models, when labeled with the radioactive element technetium (99mTc) .

HY-12761

A-836339	Cannabinoid Receptor	Cardiovascular Disease Others Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
A-836339 is a selective CB2 receptor agonist, with Ki values of 0.4 nM and 0.8 nM in humans and rats, respectively. A-836339 exhibits multiple effects such as analgesia, gastric protection, anti-inflammation, and antioxidant activity. A-836339 produces antinociceptive and analgesic activities by activating CB2 receptors in the dorsal root ganglia and spinal cord. A-836339 can also exert gastric protective effects through anti-inflammatory mechanisms (reducing TNF-α and IL-1β) and antioxidant mechanisms (enhancing the activities of CAT and SOD, and reducing H₂O₂). Radioactively labeled A-836339 can serve as a CB2-specific radioligand for autoradiography and PET imaging. A-836339 can be used in research on inflammatory pain, neuropathic pain, gastric ulcers, cerebral ischemia, etc .

HY-103178

MRE3008F20	Adenosine Receptor	Inflammation/Immunology
MRE3008F20 is a highly efficient, highly selective and radioactive adenosine A₃ receptor (AA₃R) antagonist (K_i=1.8 nM). MRE3008F20 effectively antagonises Cl-IB-MECA-induced cAMP production in resting lymphocytes with an IC₅₀ value of 5 nM. MRE3008F20 can be used in the study of AA3R .

HY-164577

BCN-DOTA-GA	Radionuclide-Drug Conjugates (RDCs)	Cancer
BCN-DOTA-GA is a cyclooctyne-linked DOTA chelator that can be labeled with radioactive zirconium-89 and used as a radionuclide-labeled drug conjugate (RDC) to target specific biomolecules, cells or tissues.

HY-164576

NCS-MP-NODA NODA-Bz-SCN	Radionuclide-Drug Conjugates (RDCs)	Cancer
NCS-MP-NODA (NODA-Bz-SCN) is a bifunctional chelator that can be used to bind to the labeled peptide DK222 with high specificity for PD-L1. The corresponding fluorinated radioactive is synthesized by the aluminum fluoride method, and NCS-MP-NODA targets DK222 to obtain the radioactive analog [18/19F]DK222. [18F]DK222 can quantify PD-L1 in vivo via PET tracking in xenograft models of multiple cancer types.

HY-158119A

PSMA-trillium Felivotide mopaxetan	PSMA	Cancer
PSMA-trillium is a PSMA targeting compound, consisting of a PSMA targeting molecule (PSMA binder), a Macropa chelating molecule, and a group that regulates pharmacokinetics (PK modifier). PSMA-trillium is a non-radioactive form of Actinium-225-PSMA-Trillium (BAY 3563254) with improved PSMA targeting and pharmacokinetic properties. PSMA-trillium can bind Ac through the Macropa chelating molecule, or the radioactive isotope ²²⁵Actinium. Actinium-225-PSMA-Trillium is a potent inhibitor of metastatic castration-resistant prostate cancer (mCRPC) .

HY-176958

OncoFAP-EN-DOTAGA	FAP	Others
OncoFAP-EN-DOTAGA is a FAP (fibroblast activation protein) targeting conjugate compound. OncoFAP-EN-DOTAGA can chelate radioactive isotopes (such as ) Ga-68 or fluorescent agent and can be used as a probe with targeting binding functions .

HY-164725

FAPI-mFS	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu . FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-W009048

Dicyclohexano-18-crown-6-ether DCH18C6; Perhydrodibenzo-18-crown-6	Biochemical Assay Reagents	Others
Dicyclohexano-18-crown-6-ether (DCH18C6) is an excellent strontium chelating agent. Dicyclohexano-18-crown-6-ether exhibits favorable extraction capacity and selectivity toward Sr (II). After chemical modification, Dicyclohexano-18-crown-6-ether is covalently bonded to an organosilicon matrix via co-condensation. DCH18C6-functionalized organosilicon materials are expected to be applied to the extraction and separation of strontium from radioactive waste liquid .

HY-P5292A

HYNIC-iPSMA TFA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-19888

GSK-1482160	P2X Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
GSK-1482160 is an orally active and blood-brain barrier penetrant P2X7 receptor (P2X7R) negative allosteric modulator with pIC₅₀s of 8.5 (human) and 6.5 (rat). GSK-1482160 reduces the efficacy of ATP at the P2X7 receptor without affecting its affinity, thereby inhibiting the release of IL-1β. GSK-1482160 is an effective radioligand and can be labeled with radioactive isotopes like 11C or 18F to image P2X7R. GSK-1482160 can be used for the studies of chronic joint pain and chronic constriction injury (CCI) .

HY-170779

DOTA-NI-FAPI-04	FAP	Cancer
DOTA-NI-FAPI-04 is a FAP inhibitor (IC₅₀ = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([68Ga]Ga/DOTA-NI-FAPI-04 and [177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact .

HY-158118

Lys(CO-C3-p-I-Ph)-OMe	DNA-PK	Cancer
Lys(CO-C3-p-I-Ph)-OMe is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules (such as Ac-PSMA-trillium). Lys(CO-C3-p-I-Ph)-OMe can increase the residence time of Ac-PSMA-trillium in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-OMe also reduces salivary gland absorption of Ac-PSMA-trillium, potentially extending its half-life. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with ¹¹¹In, it can be used as DOTA chelating agent and imaging agent. Or labeled with ²²⁵Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .

HY-124285

ATPCA hydrochloride	GABA Receptor	Others
ATPCA hydrochloride is a selective radioactive substrate for BGT1 over GAT1/GAT3 .

HY-136952

p-SCN-Bn-HOPO	Biochemical Assay Reagents	Others
p-SCN-Bn-HOPO is a bifunctional chelating agent. p-SCN-Bn-HOPO is used to bind to the radioactive isotope zirconium-89 (^89Zr) for use in ImmunoPET .

HY-172205

CHL2310	Cytochrome P450	Cancer
CHL2310 is the inhibitor for CYP46A1 with an IC₅₀ of 0.11 nM, and a K_d of 0.37 nM. CHL2310 can cross blood-brain barrier. CHL2310 can be used as a PET imaging agent, when labeled with radioactive ¹⁸F .

HY-W076740

8-Bromoadenine 8-Bromo-9H-purin-6-amine	DNA/RNA Synthesis Biochemical Assay Reagents	Others
8-Bromoadenine (8-Bromo-9H-purin-6-amine) is a DNA radiosensitizer that inhibits DNA single-strand break repair in cells. 8-Bromoadenine is a brominated derivative of adenine, and radioactive adenine can be prepared by replacing bromine with deuterium .

HY-W130177

Iodocholine iodide	Biochemical Assay Reagents	Cancer
Iodocholine iodide is a non-toxic, metabolizable "green" catalyst that can catalyze the free radical polymerization of functional polymers. Iodocholine iodide is also the non-radioactive iodide of Carbon-11 choline. C-11 Choline can be used in PET imaging and non-informative bone scintigraphy, CT or MRI to monitor various types of cancer .

HY-158125

PSMA binder-2	PSMA	Cancer
PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with ¹¹¹In, it can be used as DOTA chelating agent and imaging agent. Or labeled with ²²⁵Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P5292

HYNIC-iPSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10273

DOTA-Octreotide	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is used for research of cancer, through combination with radioactive elements. DOTA-Octreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10239A

Tyr3-Octreotate acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate acetate is a somatostatin analog. Tyr3-Octreotate acetate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate acetate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-154850

F-CRI1	STING	Cancer
F-CRI1 is a potent STING agonist with a K_d value of 40.62 nM. F-CRI1 is a radioactive probe with 18F-labeled modification. F-CRI1 can be used to study STING visualization in the tumor microenvironment .

HY-172366

BQ0413	PSMA	Cancer
BQ0413 exhibits good affinity to PSMA with a K_D of 89 pM. BQ0413 exhibits good uptake and internalization property with an internalization rate of 44% in PC3-pip cell. BQ0413 can be used as tumor imaging agent when labeled with 99mTc .

HY-116822

SSR 146977	Neurokinin Receptor	Neurological Disease
SSR 146977 is a potent and selective antagonist of the tachykinin NK3 receptor. SSR 146977 inhibits the binding of radioactive neurokinin B to NK3 receptors in Chinese hamster ovary cells, with a K_i of 0.26 nM .

HY-P10232

Hynic-toc HYNIC-Tyr3-octreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
Hynic-toc (HYNIC-Tyr3-octreotide), a octreotide derivative, can be conjugated with radioactive element for tumor imaging . Hynic-toc can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5053

Galacto-RGD	Radionuclide-Drug Conjugates (RDCs) Integrin	Cancer
Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α β selective tracer . Galacto-RGD can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10729

DOTA-Bombesin (1-14)	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Bombesin (1-14) is composed of chelator DOTA and Bombesin (HY-P0195). DOTA-Bombesin (1-14) is used for research of cancer through combination with radioactive elements. DOTA-Bombesin (1-14) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-117953

RU 59063	Prostaglandin Receptor	Endocrinology
RU 59063 is an N-substituted arylthiohydantoin compound with antiandrogenic activity and high relative binding affinity for the rat androgen receptor. RU 59063 is a nonsteroidal androgen receptor that functions as a radioactive AR radioprobe (Ki: 0.71 nM, rAR) when its trifluoromethyl group is replaced by a similar hydrophobic iodine atom .

HY-179227

HDAC6 ligand-7	HDAC	Neurological Disease
HDAC6 ligand-7 (Compound 16a) is a positron emission tomography (PET) tracer for the deacetylase 6 (HDAC6) enzyme with a K_d value of 1.66 nM. HDAC6 ligand-7 exhibits excellent HDAC6 inhibitory activity, with IC₅₀ values of 2.7 and 3.7 nM for hHDAC6 and mHDAC6, respectively, and has high selectivity for HDAC1/4/7/8. HDAC6 ligand-7 after being radioactively labeled with fluorine-18, [¹⁸F]HDAC6 ligand-7 shows varying degrees of radioactive uptake in PET, which can reflect the specific binding to HDAC6. HDAC6 ligand-7 can be used for the study of HDAC6 imaging .

HY-P10913A

HYNIC-UBI29-41 TFA	Bacterial	Infection
HYNIC-UBI29-41 TFA is composed of a bifunctional chelator HYNIC and an antimicrobial peptide UBI 29-41 (HY-P10364). HYNIC-UBI29-41 TFA retains the antibacterial properties of UBI 29-41, and exhibits good affinity to Gram-positive and Gram-negative bacteria. HYNIC-UBI29-41 TFA can be used as an imaging agent for bacterial infection detection in mouse models, when labeled with the radioactive element technetium (99mTc) .

HY-159771

FAP6-19	FAP	Cancer
FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a K_d of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.

HY-126565

Licam-C	Biochemical Assay Reagents	Others
Licam-C is a promising radiological decontaminant agent. Acting as a chelating agent, LICAM-C forms stable complexes with radioactive elements such as Plutonium (Pu) and Americium (Am). Licam-C is employed in research addressing the remediation of radioactive nucleotide contamination .

HY-19311

Upenazime	Drug Intermediate	Others
Upenazime is a non-radioactive precursor agent for diagnostic imaging .

HY-149926

Cathepsin Inhibitor 3	Ser/Thr Protease	Others
Cathepsin Inhibitor 3 (Compound 53k) is a non-radioactive intermediate in compound [ ¹⁸F] 2k radioactive synthesis, which has selectivity for cathepsin S. Cathepsin Inhibitor 3 can undergo radioactive fluorination and can be used for fluorine-18 labeling research . Cathepsin Inhibitor 3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-156982

Parpi	Biochemical Assay Reagents	Cancer
Parpi is a PET radioactive tracer with low lipotropy. Parpi can be used as a tumor imaging agent .

HY-200621

Methoxy isobutyl isonitrile	Biochemical Assay Reagents	Cancer
Methoxyisobutylisonitrile is a radioactive compound that can form a complex with technetium-99m and be used as a tracer to diagnose lung lesions and malignant thyroid nodules, etc .

HY-18037

AMG-7980	Phosphodiesterase (PDE)	Others
AMG-7980 exhibits high affinity to phosphodiesterase 10A (PDE10A), with a K_D of 0.94 nM. AMG-7980 can be used as a tracer of PDE10A, when labeled with radioactive isotope .

Cat. No.	Product Name

HY-L178

Radioprotector Library

2,808 compounds

Radiation sickness is a general term for various types and degrees of damage (or disease) occurring in the human body after exposure to ionizing radiation. Although small amounts of ionizing radiation can also cause the body to produce free radicals and ROS, causing oxidative stress, resulting in DNA damage and chromosomal aberration. Radioprotector are compounds with radiation protection that can be used to prevent/protect non-tumor cells from the harmful effects of radiation. Radioprotective compounds can prevent the damage of radioactive substances to the human body and reduce the clinical symptoms of various radioactive diseases. In addition, radioprotectors can protect normal cells from damage during radiation therapy. The ideal anti-radiation drug should not affect the sensitivity of tumor cells to radiation therapy while protecting normal cells.

MCE designs a unique collection of 2,808 radioprotectors. Radioprotector Library is an effective tool for acute Radiation Syndrome, drug combination research with radiation drugs.

Cat. No.	Product Name	Type

HY-D3174

PiF

Fluorescent Dye

PiF is a fluorescent probe with high specificity for pancreatic β-cells (Ex/Em = 535 nm/565 nm), and its fluorescence signal increases significantly with elevated insulin concentrations in in vitro experiments. PiF enables visualization of rat and human islets transplanted via the portal vein in mouse livers with low liver background signals. The fluorine atom of PiF can be replaced by radioactive ¹⁸F to prepare a PET tracer. PiF can be used for research on type 1 diabetes .

Cat. No.	Product Name	Type

HY-W782083

p-SCN-Bn-NOTA trihydrochloride

Biochemical Assay Reagents

p-SCN-Bn-NOTA trihydrochloride is a macrocyclic chelator. p-SCN-Bn-NOTA trihydrochloride can be covalently coupled to molecules such as peptides through the thiocyanate group to form hexacoordinate copper (such as ⁶⁴Cu) complexes. p-SCN-Bn-NOTA trihydrochloride specifically binds to GRPR or EGFR highly expressed on the surface of tumor cells, mediating tumor enrichment of radioactive probes. p-SCN-Bn-NOTA trihydrochloride can be used to study malignant tumors expressing GRPR or EGFR, such as prostate cancer and colorectal cancer .

HY-158067

Deferoxamine-DBCO

DFO-DBCO

Biochemical Assay Reagents

Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as ⁸⁹Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonal antibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors .

HY-W008951

Ethylenediaminetetra(methylenephosphonic acid)

EDTMP

Biochemical Assay Reagents

Ethylenediaminetetramethylenephosphonic acid (EDTMP) is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with ¹⁵³Sm and ¹⁷⁷Lu. Ethylenediaminetetramethylenephosphonic acid is used to study palliative therapy for pain associated with multiple bone metastatic cancers .

HY-W009048

Dicyclohexano-18-crown-6-ether

DCH18C6; Perhydrodibenzo-18-crown-6

Biochemical Assay Reagents

Dicyclohexano-18-crown-6-ether (DCH18C6) is an excellent strontium chelating agent. Dicyclohexano-18-crown-6-ether exhibits favorable extraction capacity and selectivity toward Sr (II). After chemical modification, Dicyclohexano-18-crown-6-ether is covalently bonded to an organosilicon matrix via co-condensation. DCH18C6-functionalized organosilicon materials are expected to be applied to the extraction and separation of strontium from radioactive waste liquid .

HY-W076740

8-Bromoadenine 8-Bromo-9H-purin-6-amine	Biochemical Assay Reagents
8-Bromoadenine (8-Bromo-9H-purin-6-amine) is a DNA radiosensitizer that inhibits DNA single-strand break repair in cells. 8-Bromoadenine is a brominated derivative of adenine, and radioactive adenine can be prepared by replacing bromine with deuterium .

HY-W130177

Iodocholine iodide	Biochemical Assay Reagents
Iodocholine iodide is a non-toxic, metabolizable "green" catalyst that can catalyze the free radical polymerization of functional polymers. Iodocholine iodide is also the non-radioactive iodide of Carbon-11 choline. C-11 Choline can be used in PET imaging and non-informative bone scintigraphy, CT or MRI to monitor various types of cancer .

Cat. No.	Product Name	Target	Research Area

HY-W1124925

DOTA-GPC3 targeting peptide 2	Radionuclide-Drug Conjugates (RDCs) Glycoprotein VI	Cancer
DOTA-GPC3 targeting peptide 2 (Sequence 30) is a RDC peptide targeting GPC3, with K_d of 0.3 nM. DOTA-GPC3 targeting peptide 2 is composed of DOTA and GPC3 targeting peptide 2. DOTA-GPC3 targeting peptide 2 can be labeled with radioactive elements .

HY-P10729A

DOTA-Bombesin (1-14) TFA	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Bombesin (1-14) TFA is composed of chelator DOTA and Bombesin (HY-P0195). DOTA-Bombesin (1-14) TFA is used for research of cancer through combination with radioactive elements. DOTA-Bombesin (1-14)TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P5290

HYNIC-PSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as ¹⁸⁸Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research . HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10273A

DOTA-Octreotide TFA	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10913

HYNIC-UBI29-41	Bacterial	Infection
HYNIC-UBI29-41 is composed of a bifunctional chelator HYNIC and an antimicrobial peptide UBI 29-41 (HY-P10364) (HY-P10364). HYNIC-UBI29-41 retains the antibacterial properties of UBI 29-41, and exhibits good affinity to Gram-positive and Gram-negative bacteria. HYNIC-UBI29-41 can be used as an imaging agent for bacterial infection detection in mouse models, when labeled with the radioactive element technetium (99mTc) .

HY-164725

FAPI-mFS	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu . FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5292A

HYNIC-iPSMA TFA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5292

HYNIC-iPSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10273

DOTA-Octreotide	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is used for research of cancer, through combination with radioactive elements. DOTA-Octreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10239A

Tyr3-Octreotate acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate acetate is a somatostatin analog. Tyr3-Octreotate acetate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate acetate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10232

Hynic-toc HYNIC-Tyr3-octreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
Hynic-toc (HYNIC-Tyr3-octreotide), a octreotide derivative, can be conjugated with radioactive element for tumor imaging . Hynic-toc can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5053

Galacto-RGD	Radionuclide-Drug Conjugates (RDCs) Integrin	Cancer
Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α β selective tracer . Galacto-RGD can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10913A

HYNIC-UBI29-41 TFA	Bacterial	Infection
HYNIC-UBI29-41 TFA is composed of a bifunctional chelator HYNIC and an antimicrobial peptide UBI 29-41 (HY-P10364). HYNIC-UBI29-41 TFA retains the antibacterial properties of UBI 29-41, and exhibits good affinity to Gram-positive and Gram-negative bacteria. HYNIC-UBI29-41 TFA can be used as an imaging agent for bacterial infection detection in mouse models, when labeled with the radioactive element technetium (99mTc) .

HY-159771

FAP6-19	FAP	Cancer
FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a K_d of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.

HY-P11774

HYNIC-3P-RGD2	Integrin	Cancer
HYNIC-3P-RGD2 is a dimeric cyclic RGD peptide with high binding affinity for integrin α_vβ₃ (IC₅₀ = 33 nM). HYNIC-3P-RGD2 acts as a precursor molecule for radiotracers and is used to detect tumor angiogenesis .

HY-P3440A

NOTA-WL12	Drug Derivative PD-1/PD-L1	Cancer
NOTA-WL12 is a conjugate of WL12 (HY-P3440) (peptide targeting PD-L1) and NOTA (HY-134418) (chelate). NOTA-WL12 shows high binding affinity to the PD-L1 (K_D = 3.012 nM). NOTA-WL12 can be labeled with radioactive isotopes for tumor imaging .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N10348

Progoitrin	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Glucosinolates Plants Brassica napus var. napobrassica (L.) Rchb. Brassicaceae Disease Research Fields Endocrinology Source Classification	Others Drug Derivative
Progoitrin is a sulfur-containing glucosinolate, as well as a naturally occurring orally active thioglycoside. Progoitrin acts as a hepatotoxin and antithyroid agent. Progoitrin is quantitatively converted to goitrin in vivo, including via a gastrointestinal hydrolysis pathway that does not require exogenous myrosinase, thereby blocking the organification of iodine in the thyroid gland and inhibiting the uptake and accumulation of radioactive iodine. Progoitrin can be used in studies related to Graves' disease .

Cat. No.	Product Name	Chemical Structure

HY-163080S

Selenium-77
Selenium-77 ( ⁷⁷Se) is a stable (non-radioactive) isotope of Selenium. Selenium-77 is both naturally occurring and produced by fission.

HY-W704091

α-Amino-β-methylaminopropionic acid-d3 hydrochloride
α-Amino-β-methylaminopropionic acid-d₃ hydrochloride is the deuterium labeled α-Amino-β-methylaminopropionic acid. Radioactive isotopes labeled compounds can be used in metabolic analysis, allowing the movement of individual atoms to be precisely tracked and quantified .

Cat. No.	Product Name		Classification

HY-158067

Deferoxamine-DBCO DFO-DBCO		DBCO
Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as ⁸⁹Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonal antibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors .

HY-149926

Cathepsin Inhibitor 3		Alkynes
Cathepsin Inhibitor 3 (Compound 53k) is a non-radioactive intermediate in compound [ ¹⁸F] 2k radioactive synthesis, which has selectivity for cathepsin S. Cathepsin Inhibitor 3 can undergo radioactive fluorination and can be used for fluorine-18 labeling research . Cathepsin Inhibitor 3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-171575

3'-Amino-2',3'-dideoxy-ATP		Nucleotide Analogs Adenine Nucleotide
3'-Amino-2',3'-dideoxy-ATP is a modified nucleotide. 3'-Amino-2',3'-dideoxy-ATP can serve as a potent chain terminator for various DNA sequencing methods, including radioactive and fluorescent sequencing, and is compatible with multiple sequencing enzymes .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

radioactive

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products